查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1676156

全球轉甲狀腺素蛋白澱粉樣變性治療市場研究報告-產業分析、規模、佔有率、成長、趨勢與預測 2025 年至 2033 年

Global Transthyretin Amyloidosis Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
出版日期: | 出版商: Value Market Research | 英文 232 Pages | 商品交期: 最快1-2個工作天內

價格

全球轉甲狀腺素蛋白澱粉樣變性治療市場規模預計將從 2024 年的 673 萬美元成長到 2033 年的 1,434 萬美元，在 2026 年至 2033 年的預測期內呈現 8.77% 的強勁年複合成長率(CAGR)。

隨著對這種罕見疾病的認知和診斷的增加，轉甲狀腺素蛋白澱粉樣變性治療市場有望大幅成長。轉甲狀腺素蛋白澱粉樣變性 (ATTR) 是一種進行性疾病，其特徵是澱粉樣蛋白在各種組織中積聚，導致器官功能障礙。 ATTR 的盛行率不斷上升，尤其是在老年人口中，推動了對有效治療方案的需求。隨著醫療保健提供者尋求改善患者的治療效果和生活品質，ATTR 治療市場預計將蓬勃發展。

技術進步在塑造轉甲狀腺素蛋白澱粉樣變性治療市場的未來方面發揮著至關重要的作用。藥物開發的創新，包括小分子療法和基因沉默技術，正在增強旨在減少澱粉樣蛋白沉積和控制症狀的治療效果。此外，診斷工具的進步使得能夠更早發現並更準確地監測疾病，這對於及時介入至關重要。隨著製藥公司不斷投入研發，轉甲狀腺素蛋白澱粉樣變性治療市場可能會更多地採用新療法並改善患者管理策略。

此外，對以患者為中心的護理和支持的日益重視正在影響轉甲狀腺素澱粉樣變性治療市場的成長軌跡。隨著患者及其家屬對疾病和可用的治療方案的了解越來越多，對滿足醫療和情感需求的全面護理計劃的需求也越來越大。這一趨勢正在推動醫療保健提供者、患者權益團體和研究人員之間的合作，以開發教育資源和支持網路，為患者在治療過程中提供幫助。隨著市場不斷發展，技術、患者參與和整體護理方法的整合將成為成功的關鍵驅動力。

我們的報告經過精心製作，為客戶提供有關各個行業和市場的全面且可操作的見解。每份報告都包含幾個關鍵部分，以確保徹底了解市場格局：

市場概覽：市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本節探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準將市場細分為不同的細分市場。該分析強調了每個部分的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本節深入介紹領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，預測特定時期內的市場規模和成長趨勢。這包括定量分析和圖形表示來說明未來的市場軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前和新興的市場趨勢、技術創新和潛在投資領域。本節提供未來市場發展和成長前景的見解。

目錄

第 1 章：前言

  • 報告描述
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究流程
    • 市場研究方法

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：轉甲狀腺素蛋白澱粉樣變性治療產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業趨勢
  • 波特五力分析
  • 市場吸引力分析
    • 按藥物類型分析市場吸引力
    • 按疾病類型進行的市場吸引力分析
    • 最終用戶的市場吸引力分析
    • 按配銷通路進行市場吸引力分析
    • 市場吸引力分析：按地區

第4章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料製造商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按藥物類型

  • 依藥物類型概覽
  • 按藥物類型進行的歷史和預測數據分析
  • 氯苯那敏
  • 派蒂西蘭
  • 伊諾特森
  • 其他

第 6 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：依疾病類型

  • 依疾病類型概覽
  • 按疾病類型進行的歷史和預測數據分析
  • 遺傳性轉甲狀腺素澱粉樣變性
  • 野生型轉甲狀腺素蛋白澱粉樣變性

第 7 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按最終用戶

  • 最終用戶概覽
  • 最終用戶的歷史和預測數據分析
  • 醫院
  • 居家護理
  • 專科診所
  • 其他

第 8 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按分銷管道

  • 按配銷通路概覽
  • 按配銷通路進行的歷史和預測資料分析
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 9 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按地區分類

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概述、歷史和預測數據銷售分析
    • 北美各細分市場銷售分析
    • 北美各國銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 歐洲各細分市場銷售分析
    • 歐洲各國銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概述、歷史和預測數據銷售分析
    • 亞太地區分部銷售分析
    • 亞太地區國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 拉丁美洲各細分市場銷售分析
    • 拉丁美洲各國銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 中東和非洲分部銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東和非洲其他地區銷售分析

第 10 章：轉甲狀腺素蛋白澱粉樣變性治療公司的競爭格局

  • 轉甲狀腺素蛋白澱粉樣變性治療市場競爭
  • 夥伴關係/合作/協議
  • 合併與收購
  • 新產品發布
  • 其他進展

第 11 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Pfizer Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • AstraZeneca
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Prothena Corporation Plc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Ionis Pharmaceuticals
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bellus Health Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Alnylam Pharmaceuticals Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Eidos Therapeutics Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Som Biotech
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Abbvie Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bausch Health Companies Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bristol Myers Squibb Company GSK Plc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Merck KGaA
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Sanofi
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，對於私人公司，可能不予涵蓋

Product Code: VMR11219273

Global Transthyretin Amyloidosis Treatment Market size is anticipated to grow from USD 6.73 Million in 2024 to USD 14.34 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 8.77% during the forecast period of 2026 to 2033.

The Transthyretin Amyloidosis Treatment Market is poised for significant growth as awareness and diagnosis of this rare disease increase. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the accumulation of amyloid proteins in various tissues, leading to organ dysfunction. The rising prevalence of ATTR, particularly among aging populations, is driving the demand for effective treatment options. As healthcare providers seek to improve patient outcomes and quality of life, the market for ATTR treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the transthyretin amyloidosis treatment market. Innovations in drug development, including small molecule therapies and gene silencing techniques, are enhancing the efficacy of treatments aimed at reducing amyloid deposits and managing symptoms. Additionally, advancements in diagnostic tools are enabling earlier detection and more accurate monitoring of the disease, which is critical for timely intervention. As pharmaceutical companies continue to invest in research and development, the transthyretin amyloidosis treatment market is likely to see increased adoption of novel therapies and improved patient management strategies.

Moreover, the growing emphasis on patient-centered care and support is influencing the transthyretin amyloidosis treatment market's growth trajectory. As patients and their families become more informed about the disease and available treatment options, there is a rising demand for comprehensive care plans that address both medical and emotional needs. This trend is driving collaboration between healthcare providers, patient advocacy groups, and researchers to develop educational resources and support networks that empower patients in their treatment journey. As the market continues to evolve, the integration of technology, patient engagement, and holistic care approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Type

  • Tafamidis
  • Patisiran
  • Inotersen
  • Others

By Diseases Type

  • Hereditary Transthyretin Amyloidosis
  • Wild Transthyretin Amyloidosis

By End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • COMPANIES PROFILED
  • Pfizer Inc
  • AstraZeneca
  • Prothena Corporation plc.
  • Ionis Pharmaceuticals
  • BELLUS Health Inc.
  • Alnylam Pharmaceuticals Inc
  • Eidos Therapeutics Inc
  • SOM BIOTECH
  • Abbvie Inc.
  • Bausch Health Companies Inc. .
  • Bristol Myers Squibb Company GSK Plc.
  • Merck KGaA
  • Sanofi
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Diseases Type
    • 3.7.3 Market Attractiveness Analysis By End User
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DRUG TYPE

  • 5.1. Overview By Drug Type
  • 5.2. Historical and Forecast Data Analysis By Drug Type
  • 5.3. Tafamidis Historic and Forecast Sales By Regions
  • 5.4. Patisiran Historic and Forecast Sales By Regions
  • 5.5. Inotersen Historic and Forecast Sales By Regions
  • 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISEASES TYPE

  • 6.1. Overview By Diseases Type
  • 6.2. Historical and Forecast Data Analysis By Diseases Type
  • 6.3. Hereditary Transthyretin Amyloidosis Historic and Forecast Sales By Regions
  • 6.4. Wild Transthyretin Amyloidosis Historic and Forecast Sales By Regions

7. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY END USER

  • 7.1. Overview By End User
  • 7.2. Historical and Forecast Data Analysis By End User
  • 7.3. Hospitals Historic and Forecast Sales By Regions
  • 7.4. Homecare Historic and Forecast Sales By Regions
  • 7.5. Specialty Clinics Historic and Forecast Sales By Regions
  • 7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1. Overview By Distribution Channel
  • 8.2. Historical and Forecast Data Analysis By Distribution Channel
  • 8.3. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 8.4. Online Pharmacy Historic and Forecast Sales By Regions
  • 8.5. Retail Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE TRANSTHYRETIN AMYLOIDOSIS TREATMENT COMPANIES

  • 10.1. Transthyretin Amyloidosis Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Pfizer Inc
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. AstraZeneca
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Prothena Corporation Plc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Ionis Pharmaceuticals
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Bellus Health Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Alnylam Pharmaceuticals Inc
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Eidos Therapeutics Inc
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Som Biotech
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Abbvie Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Bausch Health Companies Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Bristol Myers Squibb Company GSK Plc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Merck KGaA
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Sanofi
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Type (Units and USD MN)
  • Tafamidis Market Sales By Geography (Units and USD MN)
  • Patisiran Market Sales By Geography (Units and USD MN)
  • Inotersen Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Analysis By Diseases Type (Units and USD MN)
  • Hereditary Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Wild Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Analysis By End User (Units and USD MN)
  • Hospitals Market Sales By Geography (Units and USD MN)
  • Homecare Market Sales By Geography (Units and USD MN)
  • Specialty Clinics Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Analysis By Distribution Channel (Units and USD MN)
  • Hospital Pharmacy Market Sales By Geography (Units and USD MN)
  • Online Pharmacy Market Sales By Geography (Units and USD MN)
  • Retail Pharmacy Market Sales By Geography (Units and USD MN)
  • Global Transthyretin Amyloidosis Treatment Market Sales By Geography (Units and USD MN)
  • North America Market Analysis (Units and USD MN)
  • United States Market Analysis (Units and USD MN)
  • Canada Market Analysis (Units and USD MN)
  • Mexico Market Analysis (Units and USD MN)
  • Europe Market Analysis (Units and USD MN)
  • Europe Market Estimate By Country (Units and USD MN)
  • United Kingdom Market Analysis (Units and USD MN)
  • France Market Analysis (Units and USD MN)
  • Germany Market Analysis (Units and USD MN)
  • Italy Market Analysis (Units and USD MN)
  • Russia Market Analysis (Units and USD MN)
  • Spain Market Analysis (Units and USD MN)
  • Rest of Europe Market Analysis (Units and USD MN)
  • Asia Pacific Market Analysis (Units and USD MN)
  • China Market Analysis (Units and USD MN)
  • Japan Market Analysis (Units and USD MN)
  • India Market Analysis (Units and USD MN)
  • South Korea Market Analysis (Units and USD MN)
  • Australia Market Analysis (Units and USD MN)
  • South East Asia Market Analysis (Units and USD MN)
  • Rest of Asia Pacific Market Analysis (Units and USD MN)
  • Latin America Market Analysis (Units and USD MN)
  • Brazil Market Analysis (Units and USD MN)
  • Argentina Market Analysis (Units and USD MN)
  • Peru Market Analysis (Units and USD MN)
  • Chile Market Analysis (Units and USD MN)
  • Rest of Latin America Market Analysis (Units and USD MN)
  • Middle East & Africa Market Analysis (Units and USD MN)
  • Saudi Arabia Market Analysis (Units and USD MN)
  • UAE Market Analysis (Units and USD MN)
  • Israel Market Analysis (Units and USD MN)
  • South Africa Market Analysis (Units and USD MN)
  • Rest of Middle East and Africa Market Analysis (Units and USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Transthyretin Amyloidosis Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Transthyretin Amyloidosis Treatment Market Size, By Region (Units and USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Type
  • Market Attractiveness Analysis By Diseases Type
  • Market Attractiveness Analysis By End User
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Type (Units and USD MN)
  • Tafamidis Market Sales By Geography (Units and USD MN)
  • Patisiran Market Sales By Geography (Units and USD MN)
  • Inotersen Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By Diseases Type (Units and USD MN)
  • Hereditary Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Wild Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By End User (Units and USD MN)
  • Hospitals Market Sales By Geography (Units and USD MN)
  • Homecare Market Sales By Geography (Units and USD MN)
  • Specialty Clinics Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By Distribution Channel (Units and USD MN)
  • Hospital Pharmacy Market Sales By Geography (Units and USD MN)
  • Online Pharmacy Market Sales By Geography (Units and USD MN)
  • Retail Pharmacy Market Sales By Geography (Units and USD MN)
  • Global Market Sales (Units and USD MN)
  • North America Market Sales (Units and USD MN)
  • Europe Market Sales (Units and USD MN)
  • Asia Pacific Market Sales (Units and USD MN)
  • Latin America Market Sales (Units and USD MN)
  • Middle East & Africa Market Sales (Units and USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.